Surrozen Inc. (SRZN)
NASDAQ: SRZNHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
SRZN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $596.40M
- EPS (TTM)
- -$41.94
- Dividend yield
- None
- 52-week range
- 12.79 – 37.83
- Day range
- 28.25 – 30.34
- Volume / Avg
- 148.85K / 537.16K
- Beta
- —
- Shares outstanding
- 20.96M
52-week range
SRZN stock today
Surrozen (SRZN) closed at $28.46 on Nov 20, down 7.21% (-$2.21), versus the S&P 500's 3.70% decline. Trading was light, with 148.85K shares changing hands, about 28% of the average daily volume. Shares are 24.8% below their 52-week high of $37.83, set on Sep 25, 2026 and 122.5% above the 52-week low of $12.79, in the middle of the past year's range.
SRZN is up 25.9% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 115.6%. Surrozen has posted a net loss over the last twelve months (EPS of -$41.94), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Surrozen
Company profileSurrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6, or IL-6 for the treatment of DME/wet AMD/uveitic macular edema; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Craig C. Parker M.B.A.
- Headquarters
- South San Francisco, CA
- Employees
- 44
- Website
- surrozen.com
Financial highlights
Full financialsIn fiscal 2025, Surrozen generated $3.5 million in revenue, down 67.4% from fiscal 2024, its first annual decline since 2023. Surrozen reported a net loss of $242.0 million, compared with a loss of $63.6 million a year earlier. Operating margin was -1210.6%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $3.48M | $10.65M | $0 | $12.50M | $0 |
| Growth | -67.37% | — | -100.00% | — | — |
| Net income | $-242.03M | $-63.56M | $-43.04M | $-36.00M | $-54.65M |
| EPS (diluted) | $-32.37 | $-21.67 | $-21.33 | $-15.56 | $-2.21 |
Analyst forecast
ForecastConsensus (6 analysts)
strong_buy
Avg. price target
$63.50+123.12%
- Strong buy 0
- Buy 6
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 9, 2026
- EPS actual vs est.
- $-4.75 vs $-1.32
- Surprise
- -259.85%
SRZN news
All SRZN news- Surrozen, Inc. Enters Underwriting Agreement for Common Stock Offering of 1,894,540 SharesNasdaq
- Surrozen Announces Pricing of $60 Million Underwritten Offering of Common StockGlobeNewswire
- Surrozen GAAP EPS of -$11.02 misses by $9.92Seeking Alpha
- Surrozen to Present at Upcoming Healthcare Investor ConferenceGlobeNewswire
- Surrozen Announces Closing of Second Tranche of March 2025 Private Placement for $95.1 MillionGlobeNewswire
Surrozen peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CGEMCullinan Therapeutics Inc. | 8.89 | -1.98% | $577.15M | vs SRZN |
| FDMT4D Molecular Therapeutics Inc. | 10.23 | -4.57% | $576.76M | vs SRZN |
| ENTXEntera Bio Ltd. | 3.31 | +0.76% | $575.53M | vs SRZN |
| IAMIambic Therapeutics Inc. | 13.11 | -8.06% | $621.42M | vs SRZN |
| DBVTDBV Technologies S.A. ADR | 9.02 | -4.25% | $566.82M | vs SRZN |
| ETRAElectra Therapeutics Inc. | 8.11 | -9.28% | $509.85M | vs SRZN |
| ATTOAttovia Therapeutics Inc. | 15.10 | -3.08% | $690.26M | vs SRZN |
| SLDBSolid Biosciences Inc. | 6.25 | -2.95% | $697.57M | vs SRZN |
Indexes, lists and sector
Surrozen stock FAQ
What is Surrozen's stock price today?
SRZN last traded at $28.46 as of Nov 20, 4:00 PM EST, down 7.21% on the day. Prices are delayed at least 15 minutes.
Does Surrozen pay a dividend?
No. Surrozen does not currently pay a regular cash dividend.
Who is Surrozen's CEO?
Mr. Craig C. Parker M.B.A. is the chief executive officer of Surrozen Inc., which has about 44 employees.
Has SRZN ever split its stock?
Yes. The most recent SRZN stock split was a 1-for-15 split on Dec 14, 2023.
What is the SRZN 52-week high?
The 52-week high for SRZN is $37.83 and the 52-week low is $12.79. The stock is currently 24.8% below its high.